Peking Union Medical College Hospital: Carcinoma trials

The registry lists 34 Carcinoma studies with Peking Union Medical College Hospital as lead sponsor. 14 are open to participants now and 0 have results posted.

Early Phase 1 3Phase 1 4Phase 2 18Phase 3 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06907602Phase 2/3
• The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular CarcinomaNot yet recruitingNCT06750159
• 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.RecruitingNCT06613269Phase 2
• Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial CarcinomaNot yet recruitingNCT06521684
• Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular CancerRecruitingNCT06363006Phase 1
• First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine CarcinomaRecruitingNCT06070740Phase 2
• A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05981066Not applicable
• 68Ga-NY104 PET/CT Imaging in Renal Cell CarcinomaRecruitingNCT05902377Phase 2
• 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal MassesRecruitingNCT05879510Phase 2
• 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT05879471Phase 2
• Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2
• Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract CarcinomaNot yet recruitingNCT05822453Phase 2
• Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical TherapyNot yet recruitingNCT05803915Phase 2
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
• RT for Cervical Adenocarcinoma/adenosquamous CarcinomaActive, not recruitingNCT06741046
• Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B PopulationActive, not recruitingNCT06379334
• A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell CarcinomaCompletedNCT05728515Early Phase 1
• A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05636150Phase 2
• Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05536427Phase 1
• 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)Status unknownNCT05499936Not applicable
• 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma PatientsCompletedNCT05432947Not applicable
• Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Phase 2
• Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Status unknownNCT05170555Not applicable
• Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaStatus unknownNCT05161143Phase 2
• Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
• 68Ga-FAPI-04 PET/CT for the Detection of Oral CarcinomaStatus unknownNCT05003427Early Phase 1
• Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617Status unknownNCT04801264Early Phase 1
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Phase 2
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
• Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal CancerStatus unknownNCT04296747Phase 2
• 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular CarcinomaStatus unknownNCT02238769
• Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.Status unknownNCT02036216
• A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor MarkStatus unknownNCT00902902